Sigma Healthcare: A$25m EBITDA Potential Identified

Case study summary

Pricing Insight reviewed Sigma Healthcare’s pricing architecture, promotions and rebates. The engagement account identifies A$1.5m–3.0m of quick-win EBITDA potential and A$25m of longer-term potential.

Results at a glance

Status: Identified opportunity.
Quick-win potential: A$1.5m–3.0m EBITDA.
Longer-term potential: A$25m EBITDA.
These horizons are not added together without checking overlap.

Client context

Sigma’s current wholesale website describes prescription medicines, over-the-counter and front-of-shop products. Current franchise brands and network scale are not assumed to describe the historical engagement.

What pricing challenge did Sigma face?

Supplier-led promotions, cost-plus habits and rebate structures weakened pricing consistency and visibility of customer and category economics.

What did Pricing Insight do?

Pricing Insight reviewed pricing behaviour, category structures, promotions and capability. Outputs included price-architecture designs, rebate and channel-margin models, and an implementation roadmap.

What was identified?

The financial figures represent different opportunity horizons, not realised earnings. Capability and model outputs are reported separately from financial realisation.

How was the opportunity measured?

The public account does not disclose the full model, implementation costs or benefit reconciliation. Quick-win and longer-term amounts may overlap and should not be presented as a combined total.

Pricing Insight Periodic Table

Relevant capabilities: Rebate and incentive design (Rb), Price relativities and volume breaks (Rl), and Price modelling (Pm). The mapping explains the work retrospectively.